2015 HSC Section 1 Book of Articles

vaccination. Pediatr Infect Dis J . 2012;31 (9):951 – 955 26. Grif fi n MR, Zhu Y, Moore MR, Whitney CG, Grijalva CGUS. U.S. hospitalizations for pneumonia after a decade of pneumococ- cal vaccination. N Engl J Med . 2013;369(2): 155 – 163 27. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Grif fi n MR. Decline in pneumonia admissions after routine child- hood immunisation with pneumococcal conjugate vaccine in the USA: a time- series analysis. Lancet . 2007;369(9568): 1179 – 1186 28. Grijalva CG, Grif fi n MR. Unveiling the bur- den of in fl uenza-associated pneumococcal pneumonia. J Infect Dis . 2012;205(3):355 – 357 29. Viasus D, Paño-Pardo JR, Pachón J, et al; Novel In fl uenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Balti- more) . 2011;90(5):328 – 336 30. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 in fl uenza pandemic on pneumococ- cal pneumonia hospitalizations in the United States. J Infect Dis . 2012;205(3): 458 – 465 31. Örtqvist A, Bennet R, Rinder MR, Lindblad H, Eriksson M. Effectiveness of the monovalent AS03-adjuvanted in fl uenza A(H1N1)pdm09 vaccine against hospitalization in children because of in fl uenza. Vaccine . 2012;30(39): 5699 – 5702 32. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumo- niae in virus-associated pneumonia. Nat Med . 2004;10(8):811 – 813 33. Weinberger DM, Givon-Lavi N, Shemer-Avni Y, et al. In fl uence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis . 2013; 19(7):1084 – 1091 34. Grijalva CG, Zhu Y, Nuorti JP, Grif fi n MR. Emergence of parapneumonic empyema in the USA. Thorax . 2011;66(8):663 – 668 35. Grijalva CG, Nuorti JP, Zhu Y, Grif fi n MR. Increasing incidence of empyema compli- cating childhood community-acquired pneu- monia in the United States. Clin Infect Dis . 2010;50(6):805 – 813 36. Burgos J, Falcó V, Pahissa A. The increasing incidence of empyema. Curr Opin Pulm Med . 2013;19(4):350 – 356 37. Li ST, Tancredi DJ. Empyema hospital- izations increased in US children despite pneumococcal conjugate vaccine. Pediat- rics . 2010;125(1):26 – 33

4. Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet . 2013;381(9875):1405 – 1416 5. Wald ER, Applegate KE, Bordley C, et al; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics . 2013;132(1). Available at: www.pediatrics. org/cgi/content/full/132/1/e262 6. Benninger M, Brook I, Farrell DJ. Disease severity in acute bacterial rhinosinusitis is greater in patients infected with Streptococcus pneumoniae than in those infected with Haemophilus in fl uenzae . Otolaryngol Head Neck Surg . 2006;135(4): 523 – 528 7. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for pre- venting vaccine-type invasive pneumococ- cal disease and X-ray de fi ned pneumonia in children less than two years of age. Cochrane Database Syst Rev . 2009; (4): CD004977 8. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vac- cine. Pediatr Infect Dis J . 2012;31(5):501 – 508 9. Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneu- mococcal conjugate vaccination (PCV7) programme on childhood hospital ad- missions for bacterial pneumonia and empyema in England: national time-trends study, 1997 – 2008. Thorax . 2010;65(9):770 – 774 10. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conju- gate vaccine on rates of community ac- quired pneumonia in children and adults. Vaccine . 2008;26(38):4947 – 4954 11. Lee GE, Lorch SA, Shef fl er-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics . 2010;126(2):204 – 213 12. Elston JW, Santaniello-Newton A, Meigh JA, et al. Increasing incidence of invasive pneumococcal disease and pneumonia de- spite improved vaccination uptake: sur- veillance in Hull and East Yorkshire, UK, 2002 – 2009. Epidemiol Infect . 2012;140(7): 1252 – 1266 13. Benninger MS, Manz R. The impact of vac- cination on rhinosinusitis and otitis media. Curr Allergy Asthma Rep . 2010;10(6):411 – 418 14. Shapiro DJ, Gonzales R, Cabana MD, Hersh AL. National trends in visit rates

and antibiotic prescribing for children with acute sinusitis. Pediatrics . 2011;127 (1):28 – 34 15. Fanella S, Singer A, Embree J. Presentation and management of pediatric orbital cel- lulitis. Can J Infect Dis Med Microbiol . 2011; 22(3):97 – 100 16. Stockholm County Child Healthcare Ser- vices. Annual Report . Stockholm, Sweden: Stockholm County Child Healthcare Ser- vices; 2012 17. Regional Planning Of fi ce. Of fi cial statis- tics, Stockholm County Council. Avail- able at: www.tmr.sll.se/Global/Dokument/ Statistik/Befolkningsutveckling/2012_1_s_ Befolkningsutvecklingen_2011.pdf 18. Wagner AK, Soumerai SB, Zhang F, Ross- Degnan D. Segmented regression analysis of interrupted time series studies in med- ication use research. J Clin Pharm Ther . 2002;27(4):299 – 309 19. Gebski V, Ellingson K, Edwards J, Jernigan J, Kleinbaum D. Modelling interrupted time series to evaluate prevention and control of infection in healthcare. Epidemiol Infect . 2012;140(12):2131 – 2141 20. Peña MT, Preciado D, Orestes M, Choi S. Orbital complications of acute sinusitis: changes in the post-pneumococcal vaccine era. JAMA Otolaryngol Head Neck Surg . 2013;139(3):223 – 227 21. Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in patho- genicity following widespread use of pneumococcal conjugate vaccine. Otolar- yngol Head Neck Surg . 2008;138(3):274 – 278 22. McNeil JC, Hulten KG, Mason EO Jr, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in chil- dren with chronic sinusitis. Pediatr Infect Dis J . 2009;28(9):766 – 768 23. Feikin DR, Kagucia EW, Loo JD, et al; Sero- type Replacement Study Group. Serotype- speci fi c changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med . 2013; 10(9):e1001517 24. Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of chil- dren with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol . 2007;71(4):575 – 579 25. Magnus MC, Vestrheim DF, Nystad W, et al. Decline in early childhood re- spiratory tract infections in the Norwe- gian mother and child cohort study after introduction of pneumococcal conjugate

PEDIATRICS Volume 134, Number 6, December 2014

141